Axial Psoriatic Arthritis When NSAIDs Fail to Control Symptoms

Patients with clinically relevant axial psoriatic arthritis are initially managed with NSAIDs. When adequate axial symptom relief is not achieved within the expected timeframe, a defined next-line protocol guides the therapeutic decision.

Clinical Scenario

This protocol is for patients with clinically relevant axial psoriatic arthritis — where the axial component drives the treatment strategy and the choice of therapy must account for the specific biology of axial disease.

Previous Step — NSAID Target Not Met

The prior step uses NSAIDs (with continuous use considered when they produce significant symptom improvement). The defined goal is relief of axial symptoms within 4 weeks. Failure to reach this target is the trigger for escalation to this protocol.

Next-Line Approach — Partial Overview

After NSAID failure in axial disease, the evidence-based pathway involves a choice from several distinct classes of biologic or targeted therapy. Not all pathways are appropriate here — one major pathway is specifically not recommended for axial disease. The complete agent selection, preferred ordering, and safety considerations are available in the full protocol.

Treatment Targets

Success is assessed at two defined timepoints:

Improvement at 3 months Remission or low disease activity at 6 months

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1136/ard-2024-225531

In patients with clinically relevant axial disease with an insufficient response to NSAIDs, therapy with an IL-17A inhibitor, a TNF inhibitor, an IL-17 A/F inhibitor or a JAKi should be considered.
Treatment should be aimed at reaching the target of remission or, alternatively, low disease activity, by regular disease activity assessment and appropriate adjustment of therapy.

View source ↗